Nuvectis Pharma, Inc.

Compare

111 Followers

NVCT Stock Chart & Stats

$6.20

-$0.26(-4.17%)

At close: Jan 08 4:00 PM EST

$6.20

-$0.26(-4.17%)

Day’s Range― - ―

52-Week Range$4.44 - $11.80

Previous CloseN/A

Volume31.37K

Average Volume (3M)101.04K

Market Cap

$172.34M

Enterprise Value$132.81M

Total Cash (Recent Filing)$26.79M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.69

Next Earnings

Nov 11, 2025

EPS Estimate

-0.25

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.30

Shares Outstanding25,456,848

10 Day Avg. Volume117,260

30 Day Avg. Volume101,040

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)9.53

Price to Sales (P/S)0.00

P/FCF Ratio-7.56

Enterprise Value/Market Cap0.77

Enterprise Value/Revenue4.96

Enterprise Value/Gross Profit14.69

Enterprise Value/Ebitda-5.85

Forecast

1Y Price Target

$15.67

Price Target Upside152.74% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentPhase 1b initiation marks next step in NXP900’s clinical development.

Financial StabilityManagement believes the current cash provides runway for the next two years.

Safety ProfileOnce-daily NXP900 demonstrated an acceptable safety profile with mainly Grade 1-2 diarrhea, fatigue, and nausea.

Bears Say

NXP800 DevelopmentBased on these early data the company has decided not pursue development of NXP800 in ovarian cancer.

Product Focus ShiftFollowing disappointing results from NXP800's Phase 1 trial, management is now solely focused on its lead asset, NXP900 for lung cancer.

Stock ImpactShares are trading down ~7% due to the NXP800 data being less than favorable.

Nuvectis Pharma News

Nuvectis Pharma provides highlights from NXP900 poster presentations

Nuvectis Pharma (NVCT) provided highlights for NXP900 poster presentations that took place last week at the 2025 AACR-NCI-EORTC...

4d ago

NVCT

Nuvectis Pharma’s Phase 1 Study of NXP900: A Potential Game-Changer in Cancer Treatment

Nuvectis Pharma, Inc. (($NVCT)) announced an update on their ongoing clinical study. Nuvectis Pharma, Inc. is currently conducting...

4d ago

NVCT

Promising Safety and Efficacy of Nuvectis Pharma’s NXP900 Drives Buy Recommendation

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Nuvectis Pharma. The associated price target...

4d ago

NVCT

Nuvectis Pharma Appoints Juan Sanchez to Board

Nuvectis Pharma ( ($NVCT) ) has provided an update. On September 22, 2025, Nuvectis Pharma appointed Juan Sanchez,...

1M ago

NVCT

Nuvectis Pharma appoints Juan Sanchez to board of directors

Nuvectis Pharma (NVCT) announced the appointment of Juan Sanchez, MD, to its Board of Directors. Dr. Sanchez is...

1M ago

NVCT

Nuvectis Pharma initiates NXP900 program

Nuvectis Pharma (NVCT) announced the initiation of the Phase 1b program for NXP900. Published first on TheFly –...

3M ago

NVCT

Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments

In a report released yesterday, Naz Rahman from Maxim Group reiterated a Buy rating on Nuvectis Pharma, with...

3M ago

NVCT

Nuvectis Pharma Reports Q2 2025 Financial Results and Progress

Nuvectis Pharma, Inc. ( ($NVCT) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

NVCT

Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year

Cash and cash equivalents were $26.8M vs. $18.5M as of December 31, 2024. CEO Ron Bentsur commented, “In...

3M ago

NVCT

Strategic Pipeline Reprioritization and Promising Clinical Progress Drive Buy Rating for Nuvectis Pharma

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Nuvectis Pharma, reducing the price target to...

3M ago

NVCT

Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nuvectis Pharma (NVCT) to $10 from $15 and keeps a...

3M ago

NVCT

Strategic Focus on NXP900 Drives Buy Rating for Nuvectis Pharma

In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Nuvectis Pharma, with...

3M ago

NVCT

Nuvectis Pharma provides final clinical data update from NXP800 Phase 1b study

Nuvectis Pharma (NVCT) provided the final clinical data update from the Phase 1b study of NXP800 in recurrent,...

3M ago

NVCT

Promising Potential of NXP900 in Combination Therapy for Resistant Lung Cancer Justifies Buy Rating

Maxim Group analyst Naz Rahman has reiterated their bullish stance on NVCT stock, giving a Buy rating yesterday....

4M ago

NVCT

NVCT FAQ

What was Nuvectis Pharma, Inc.’s price range in the past 12 months?

Nuvectis Pharma, Inc. lowest stock price was $4.44 and its highest was $11.80 in the past 12 months.

What is Nuvectis Pharma, Inc.’s market cap?

Nuvectis Pharma, Inc.’s market cap is $172.34M.

When is Nuvectis Pharma, Inc.’s upcoming earnings report date?

Nuvectis Pharma, Inc.’s upcoming earnings report date is Nov 11, 2025 which is in 11 days.

How were Nuvectis Pharma, Inc.’s earnings last quarter?

Nuvectis Pharma, Inc. released its earnings results on Aug 05, 2025. The company reported -$0.3 earnings per share for the quarter, missing the consensus estimate of -$0.252 by -$0.048.

Is Nuvectis Pharma, Inc. overvalued?

According to Wall Street analysts Nuvectis Pharma, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvectis Pharma, Inc. pay dividends?

Nuvectis Pharma, Inc. does not currently pay dividends.

What is Nuvectis Pharma, Inc.’s EPS estimate?

Nuvectis Pharma, Inc.’s EPS estimate is -0.25.

How many shares outstanding does Nuvectis Pharma, Inc. have?

Nuvectis Pharma, Inc. has 25,456,848 shares outstanding.

What happened to Nuvectis Pharma, Inc.’s price movement after its last earnings report?

Nuvectis Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, missing expectations of -$0.252. Following the earnings report the stock price went down -5.35%.

Which hedge fund is a major shareholder of Nuvectis Pharma, Inc.?

Currently, no hedge funds are holding shares in NVCT

Nuvectis Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-150.12%

Trailing 12-Months

Asset Growth

47.60%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvectis Pharma, Inc.

Nuvectis Pharma (NVCT) is a biopharmaceutical company that operates within the healthcare and biotechnology sectors. The company focuses on the development and commercialization of innovative therapeutics for the treatment of cancer. Nuvectis Pharma leverages advanced scientific research to create novel drugs aimed at addressing unmet medical needs in oncology.

Nuvectis Pharma (NVCT) Earnings & Revenues

Historic Earnings Reports

NVCT Stock 12 Month Forecast

Average Price Target

$15.67

▲(152.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","21":"$21","8.25":"$8.25","12.5":"$12.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,8.25,12.5,16.75,21],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.815384615384615,8.830769230769231,9.846153846153847,10.861538461538462,11.876923076923077,12.892307692307693,13.907692307692308,14.923076923076923,15.938461538461539,16.953846153846154,17.96923076923077,18.984615384615385,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.4823076923076925,8.164615384615384,8.846923076923076,9.52923076923077,10.211538461538462,10.893846153846155,11.576153846153847,12.258461538461539,12.94076923076923,13.623076923076923,14.305384615384616,14.98769230769231,{"y":15.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.8,7.046153846153846,7.292307692307692,7.538461538461538,7.7846153846153845,8.03076923076923,8.276923076923076,8.523076923076923,8.76923076923077,9.015384615384615,9.26153846153846,9.507692307692308,9.753846153846155,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.19,"date":1698796800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.37,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.41,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.76,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.69,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.35,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >